CCDC 1435400: Experimental Crystal Structure Determination
Alexander V. Kel’in(Alnylam Pharmaceuticals (United States)), Muthiah Manoharan(Alnylam Pharmaceuticals (United States)), Muthusamy Jayaraman(Forma Therapeutics (United States)), Saeed Khan, Nate Taneja(Alnylam Pharmaceuticals (United States)), Martin A. Maier(Alnylam Pharmaceuticals (United States)), Rajar M. Manoharan(Alnylam Pharmaceuticals (United States)), Ivan Zlatev(Alnylam Pharmaceuticals (United States)), Kallanthottathil G. Rajeev(Alnylam Pharmaceuticals (United States)), Martin Egli(Vanderbilt University), Jonathan O′Shea(Alnylam Pharmaceuticals (United States)), Anna Bisbe(Alnylam Pharmaceuticals (United States)), Klaus Charissé(Alnylam Pharmaceuticals (United States)), Joel M. Harp(Vanderbilt University)
Cited by 0
Related Papers
Rational design of cationic lipids for siRNA delivery
|Nature Biotechnology|2010|1.8k
The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs
|Nature Nanotechnology|2019|1.6k
Maximizing the Potency of siRNA Lipid Nanoparticles for Hepatic Gene Silencing In Vivo**
|Angewandte Chemie International Edition|2012|1.2k
Targeted Delivery of RNAi Therapeutics With Endogenous and Exogenous Ligand-Based Mechanisms
|Molecular Therapy|2010|1.2k
A combinatorial library of lipid-like materials for delivery of RNAi therapeutics
|Nature Biotechnology|2008|1.2k